Author: Healio ophthalmology

Endothelial cell counts similar in donor corneas with, without HIV

SEATTLE — Donor corneas with or without HIV have no significant differences in endothelial cell counts, according to a poster here.“Since the patients were not known to be HIV-positive according to their medical records and interview with family members, it may be that the infection was relatively early in these patients,” John A. Gonzales, MD, and colleagues said in a poster presented at the Association for Research in Vision and Ophthalmology meeting.

Costs calculated for vitrectomy claims

SEATTLE — In patients with newly diagnosed macular hole, only 24% had a vitrectomy performed within 1 year, according to a poster presented here.Using Medicare claims data from 2008 to 2010, Sunil Srivastava, MD, and colleagues calculated the mean cost in claims for those patients to be $5,900 greater than for patients who did not have vitrectomy. Over 2 years, the average allowed charges for ophthalmic services per vitrectomy patient was $7,702.

DME causes significant financial hardship for long-haul truck drivers

SEATTLE — Focus groups of current and former truck drivers diagnosed with diabetic macular edema found that diabetes and DME can cause a significant financial burden for drivers, according to a poster here.Sunil S. Patel, MD, PhD, and colleagues at West Texas Retina Consultants recruited four former and four current long-haul truckers to participate in two focus groups. They also had the truckers file a 90-day diary of out-of-pocket expenses as well as record the time they and their caregivers spent treating diabetes and DME. The investigators shared their results (Read more...)

Incidence of microbial keratitis after laser vision correction low

SEATTLE —The incidence of microbial keratitis after laser vision correction is one in 6,300 patients, according to a poster presented here. Steven C. Schallhorn, MD, told Ocular Surgery News at the Association for Research in Vision and Ophthalmology meeting that he and colleagues were able to calculate this incidence by using a large cohort of consecutive patients who underwent refractive surgery from January 2008 to December 2012.

Study correlates characteristics of diabetic microaneurysms with AOSLO and SD-OCT

SEATTLE — The combination of ultra-high resolution adaptive optics scanning laser ophthalmoscope imaging with spectral domain optical coherence tomography can provide detailed assessment of the in vivo interplay of retinal vascular and neural pathology, according to a speaker here.“Microaneurysms are common and can be a hallmark sign of diabetic retinopathy,” Jennifer K. Sun, MD, said at the Association for Research in Vision and Ophthalmology meeting.

Selective, non-selective alpha blockers present risk for IFIS during cataract surgery

SEATTLE — Both selective and non-selective alpha blockers taken before cataract surgery were associated with intraoperative floppy iris syndrome in a retrospective study of a large Veterans Health Administration database, according to a poster here.“Altogether, complication rates were fairly low,” David E. Vollman, MD, told Ocular Surgery News at the Association for Research in Vision and Ophthalmology meeting.

Caffeine improves saccade velocity after exercise fatigue

SEATTLE — Fatigue-induced impairments in saccade velocity after prolonged strenuous exercise can be reversed by caffeine, according to a poster presented here.“It has been proven in primates that fatigue affects saccadic eye movement,” poster presenter Charlotte J. Connell told Ocular Surgery News at the Association for Research in Vision and Ophthalmology meeting. With that premise, the researchers randomized 10 cyclists to receive either placebo or caffeine during a 180-minute cycling protocol. Saccadic eye movements and global motion perception were assessed before and after the protocol.

Surgeons, patients satisfied after bilateral implantation of multifocal IOL

SEATTLE — Both patients and surgeons are satisfied after bilateral implantation of an aspheric diffractive multifocal one-piece IOL, according to a poster presented here.The Tecnis multifocal one-piece IOL (ZMB00, Abbott Medical Optics) was bilaterally implanted in 106 patients with corneal astigmatism by surgeons who had not implanted this lens previously, and then both clinical and satisfaction assessments were made in a prospective, multicenter, open-label observation study.

NSAID reduces inflammation after cataract surgery

SEATTLE — Once-daily 0.07% bromfenac ophthalmic solution safely reduces ocular inflammation after cataract surgery, according to a poster here. “Compared to placebo, low-concentration, modified bromfenac ophthalmic solution dosed once daily effectively and safely reduced ocular inflammation associated with cataract surgery,” James A. Gow and colleagues said in a poster presented at the Association for Research in Vision and Ophthalmology annual meeting.

NEI announces ‘audacious’ goal for research

SEATTLE — To regenerate neurons and neural connections in the eye and visual system is the “audacious” target that the National Eye Institute aims to accomplish in the next 10 to 15 years, the director of the NEI announced here.“The Audacious Goals Initiative is part of the trajectory of a remarkable past decade,” Paul A. Sieving, MD, PhD, said at the Association for Research in Vision and Ophthalmology annual meeting, where he presented the NEI’s focus of future research. Vision has been “front and center” of molecular and genetic advancements (Read more...)

Higher success with ocriplasmin for vitreomacular traction found in certain population groups

SEATTLE — When considering using ocriplasmin for vitreomacular traction, the most important consideration is the size of the macular traction, but age, presence of epiretinal membrane and whether the eye is phakic also need to be taken into account, according to a speaker here. Speaking at the Cole Eye Institute Retina Summit held before the Association for Research in Vision and Ophthalmology meeting, Peter K. Kaiser, MD, said that if the macular adhesion is broad, patients did not do as well as patients with focal areas of adhesion.

Two anti-VEGFs demonstrate no visual acuity difference at 2 years, CATT author says

SEATTLE — Despite what many have said, the Comparison of Age-Related Macular Degeneration Treatment Trials showed ranibizumab and bevacizumab are equivalent for visual acuity, according to an expert speaking here. “We are talking about a 0.5 D difference,” Daniel F. Martin, MD, said regarding visual acuity results in the CATT. “People see it the way they want to see it, but one line is really trivial. This is noise. There is no statistically significant difference at 2 years.”

Allegro, Senju to collaborate on integrin peptide therapy in Japan

Senju Pharmaceutical will co-develop and market Allegro Ophthalmics’ integrin peptide therapy in Japan under an agreement between the two companies, according to a joint news release. The first-in-class therapy targets integrin with an oligopeptide to reduce leakage from and growth of aberrant blood vessels. It is intended for use as an intravitreal injection in patients with vascular eye diseases, including diabetic macular edema and wet age-related macular degeneration, the release said.

Alterations in AREDS formula recommended

SEATTLE — The addition of lutein/zeaxanthin to and the subtraction of beta carotene from the AREDS supplement formula was recommended by investigators in the Age-Related Eye Disease Study 2. Emily Y. Chew, MD, lead author of the National Eye Institute study published online in Journal of the American Medical Association, told colleagues here at the Association for Research in Vision and Ophthalmology meeting that study data pointed to a replacement formula for the AREDS formula that until now has been recommended for patients at risk for progression of age-related macular (Read more...)

Nanotechnology firm to form ophthalmology company

Liquidia Technologies, a nanotechnology-based health care company, will form a new ophthalmology business to move into a high-growth therapeutic area, according to a company news release. The company’s likely lead product is a glaucoma treatment that is expected to enter clinical trials in 2014, the release said.The company uses a proprietary technology platform, called Print, to allow for rapid development and production of precisely engineered particles of almost any size, shape and composition. Liquidia will release additional details on the ophthalmic company later in the second quarter, according to the (Read more...)